The FDA has approved capivasertib for the treatment of breast cancers with certain mutations. The U.S. Food and Drug Administration (FDA) has approved capivasertib (Truqap), in combination with fulvestrant (Faslodex), for the treatment of...
The FDA has approved pembrolizumab for the first-line treatment of certain HER2-negative gastric and gastroesophageal junction cancers. The U.S. Food and Drug Administration (FDA) has approved pembrolizumab (Keytruda), in combination with a chemotherapy regimen...
The FDA has approved repotrectinib for certain patients with non-small cell lung cancer harboring a ROS1 mutation or rearrangement. The U.S. Food and Drug Administration (FDA) has approved repotrectinib (Augtyro) for the treatment of...
Stool test for signs of cancer, often collected at home, sometimes fails due to inadequate sampling, according to a study in the AACR Journal Cancer Epidemiology, Biomarkers & Prevention. About a tenth of the...
Our immune systems are equipped to recognize and destroy cancer cells—if they can find them, that is. And with tens of trillions of cells in the human body and the masterful hiding skills of...
Sun exposure is an occupational hazard around the globe, and a dormant virus can cause immunotherapy complications.
The FDA has approved another inhibitor of the VEGF receptor family for patients with metastatic, heavily pretreated colorectal cancer. The U.S. Food and Drug Administration (FDA) has approved fruquintinib (Fruzaqla) for adult patients with...
Cancers are driven by unique genetic alterations, so what if we targeted these alterations to treat the cancer? It seems straightforward, but it’s easier said than done.
New recommendation suggests ongoing lung cancer screening for those with heavy smoking history even after quitting, and more.
In the opening keynote session of the AACR Special Conference on Pancreatic Cancer, which took place September 27-30 in Boston, co-chair Jen Jen Yeh, MD, exemplified the excitement and passion exuding from the researchers...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More